PURPOSE: The evaluation of plasma testing for the @entity470 resistance mutation @entity9513 in NSCLC @entity1 has not been broadly explored. We investigated the detection of @entity470 activating and @entity9513 mutations in matched @entity5 tissue and plasma, mostly from @entity1 with acquired resistance to first-generation @entity470 inhibitors. EXPERIMENTAL DESIGN: Samples were obtained from 2 studies, an observational study and a phase 1 trial of @entity69286 , a mutant-selective inhibitor of @entity470 that targets both activating mutations and @entity9513 . Plasma testing was performed with the cobas   @entity470 plasma test and BEAMing. RESULTS: The positive percent agreement (PPA) between cobas   plasma and @entity5 results was 73% (55/75) for activating mutations and 64% (21/33) for @entity9513 . The PPA between BEAMing plasma and @entity5 results was 82% (49/60) for activating mutations and 73% (33/45) for @entity9513 . Presence of extrathoracic (M1b) vs. @entity66 was found to be strongly associated with ability to identify @entity470 mutations in plasma (p < 0.001). @entity69286 objective response rates (ORR) were 52% (95% CI, 31-74%) for cobas   @entity5 @entity9513 -positive and 44% (95% CI, 25-63%) for BEAMing plasma @entity9513 -positive @entity1 . A drop in plasma mutant @entity470 levels to  <=10 molecules/mL was seen by Day 21 of treatment in 7 of 8 @entity1 with documented partial response. CONCLUSIONS: These findings suggest the cobas   and BEAMing plasma tests can be useful tools for non-invasive assessment and monitoring of the @entity9513 resistance mutation in NSCLC, and could complement @entity5 testing by identifying @entity9513 mutations missed because of @entity5 heterogeneity or biopsy inadequacy.

Assessment of @entity470 mutation status in matched plasma and @entity5 tissue of NSCLC XXXX from a phase 1 study of @entity69286 ( @entity69286 ).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity69286 :: ('MESH:C000589977', 'Chemical') :: ['rociletinib', 'Rociletinib'] @entity66 :: ('MESH:D004194', 'Disease') :: ['intrathoracic (M1a/M0) disease'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity9513 :: ('p|SUB|T|790|M', 'ProteinMutation') :: ['T790M']
@entity1 :: (9606,Species) :: ['patients']
